癌症与抗合成酶综合征的关联:一项回顾性多中心研究
相关实验视频
Updated: Sep 19, 2025

13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
135.4K
Laura Bucy1, Hervé Devilliers2, Paul Decker1
1Internal Medicine and Clinical Immunology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France.
The American journal of medicine
|June 3, 2025
概括
与癌症相关的肌肉炎在抗合成酶综合征中很常见,影响11.4%的患者. 早期癌症查至关重要,特别是对于有癌症病史的老年人来说,因为死亡风险增加.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 抗合成酶综合征是一种罕见的自身免疫性疾病.
- 癌症相关肌肉炎 (CAM) 是自身免疫性疾病的一种罕见并发症.
- 在抗合成酶综合征中CAM的发生率和预后影响尚未得到充分确立.
研究的目的:
- 为了确定在患有抗合成酶综合征的患者中CAM的发生率.
- 在这个人群中识别与CAM相关的因素.
- 评估CAM对患者预后的影响.
主要方法:
- 对患有抗合成酶综合征的成年患者进行了回顾性多中心研究.
- 多变量逻辑回归用于识别癌症预测因子.
- 无监督分析用于患者聚类.
- 考克斯比例危险模型用于死亡率评估.
主要成果:
- 11.4%的患者患有CAM,与一般人群相比,标准化发病率为5.4.
- 高龄和癌症史独立与CAM相关.
- 康复治疗患者的整体存活率更差,是死亡的独立预测因素.
- CAM集群显示年龄较大,肌肉参与程度较轻,Jo-1抗体较低.
结论:
- 在抗合成酶综合征中,CAM并不罕见,其发病率高于一般人群.
- CAM与预后明显恶化和死亡率增加有关.
- 在有癌症史的老年抗合成酶综合征患者中,应优先进行癌症查.
更多相关视频
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
5.8K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458